RESEARCH
Open Access

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study

Bruce Wang1, Paolo Ventura2, Kei-ichiro Takase3, Manish Thapar4, David Cassiman5, Ilja Kubisch6, Shangbin Liu7, Marianne T. Sweetser7 and Manisha Balwani8

Abstract
Background: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy. We evaluated the AHP disease burden in patients aged ≥ 12 years in a post hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic that targets the enzyme ALAS1 to decrease ALA and PBG production. We analyzed baseline AHP severity via chronic symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality of life (QOL) and evaluated givosiran (2.5 mg/kg monthly) in patients with and without prior hemin prophylaxis on number and severity of attacks and pain scores during and between attacks.

Results: Participants (placebo, n = 46; givosiran, n = 48) included patients with low and high annualized attack rates (AARs; range 0–46). At baseline, patients reported chronic symptoms (52%), including nausea, fatigue, and pain; comorbidities, including neuropathy (38%) and psychiatric disorders (47%); concomitant medications, including chronic opioids (29%); hemin-associated complications (eg, iron overload); and poor QOL (low SF-12 and EuroQol visual analog scale scores). A linear relationship between time since diagnosis and AAR with placebo suggested worsening of disease over time without effective treatment. Givosiran reduced the number and severity of attacks, days with worst pain scores above baseline, and opioid use versus placebo.

Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran.

Keywords: Acute hepatic porphyria, Givosiran, Disease burden, Porphyria attack, Chronic symptoms, Quality of life

Background
Acute hepatic porphyria (AHP) is a family of rare genetic diseases, each arising from a deficiency in an enzyme involved in hepatic heme biosynthesis [1]. These enzyme defects cause depletion of free heme and increase the demand for hepatic heme, resulting in up-regulation of the ALAS1 enzyme and overproduction of the toxic heme intermediates delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) [2]. Accumulation of ALA and PBG is thought to cause injury primarily to the nervous system, as well as to other organs, such as the liver and kidneys [2–4]. Of the four subtypes of AHP, the most common is acute intermittent porphyria (AIP) [1]. AHP manifests predominantly in females between the ages of...
Liver transplantation is considered a last resort for patients with severe recurrent attacks that do not respond to hemin [5, 26, 27]. It is not suitable for most patients, and there is a shortage of donors [11, 28]. It also has a significant risk of morbidity and mortality that is comparable to that faced by patients who received transplants for other metabolic diseases [11, 25, 27].

Thus, treatment options for recurrent AHP were limited before the approval of givosiran, a subcutaneously administered RNA interference (RNAi) therapeutic that specifically targets ALAS1 messenger RNA in the liver to reduce production of ALA and PBG [29, 30]. Givosiran is indicated for the treatment of AHP in adults (United States, Brazil, Canada) and adolescents aged 12 years and older (European Economic Area, United Kingdom, Switzerland, Japan) [31–34] based on the results of the phase 3 ENVISION trial [35]. In ENVISION (NCT03338816), givosiran treatment was associated with a 74% reduction in the mean annualized rate of composite porphyria attacks (AAR) in patients with AIP compared with placebo (3.2 vs. 12.5, respectively; \( P < 0.001 \)) [35]. Givosiran treatment also reduced urinary ALA and PBG levels and hemin use and was associated with improvement in pain and QOL assessment scores. Continued treatment through month 24 led to sustained reductions in ALA and PBG levels, porphyria attacks, and hemin use, and to further improvements in QOL and other patient-reported outcomes [36]. The proportion of patients with no attacks increased over time, with 83% of patients who received continuous givosiran treatment remaining attack-free during the 3 months prior to Month 24 [36]. The safety profile of givosiran was acceptable, and most adverse events (AEs) were mild or moderate in severity [35, 36].

This post hoc analysis used data from the ENVISION trial to evaluate the disease burden associated with AHP, including patients with a low rate of acute attacks (<7 attacks or <12 attacks in the previous 12 months among patients who were and were not receiving hemin at baseline, respectively). The efficacy of givosiran in patients with and without prior hemin use was also assessed, including patient-reported pain scores during and between attacks.

**Methods**

**ENVISION trial design**

The study population was defined as patients aged ≥12 years with a diagnosis of AHP, an elevated level of urinary ALA or PBG (≥4 times the upper limit of normal), and either a confirmed pathogenic mutation associated with AHP or biochemical and clinical criteria consistent with a diagnosis of AHP [35]. Patients were also required to have experienced ≥2 porphyria

20 and 40 years [5, 6], and the overall symptomatic prevalence is 1 per 100,000 persons [7, 8]. While most symptomatic patients experience only a few attacks in their lifetime, up to 8% have recurrent attacks (≥4 attacks per year) [9].

AHP is a multisystem disease characterized by disabling acute neurovisceral attacks, most often including severe abdominal pain, vomiting, muscle weakness, hypertension, and changes in mental status [2]. Chronic manifestations occur between attacks and progress over the disease course [2, 6, 10, 11]. In a multinational natural history study of 112 patients with AHP experiencing recurrent attacks (EXPLORE), 77% of attacks required treatment at a healthcare facility and/or administration of hemin [11]. Attacks not treated promptly or that frequently recur may lead to progressive or irreversible neuropathy and prolonged debilitation [2, 11]. Approximately 59% of patients with recurrent attacks will develop chronic kidney disease [12]. Recurrent AHP also has a long-term impact on mental functioning, affecting activities of daily living [6, 10, 13]. Patients report diminished quality of life (QOL) and significant economic burden [11, 14].

Early treatment is important to prevent disease progression [5, 15]. There is a need for treatments that not only reduce or eliminate acute attacks, but also improve chronic manifestations of recurrent AHP. Prevention strategies include identifying and avoiding triggers that may precipitate acute attacks [16, 17]. However, some triggers, such as stress, may not always be avoidable [17, 18]. Furthermore, many patients continue to experience chronic symptoms between attacks [6, 10, 11]. Opioids are used to manage abdominal, limb, and back pain [17], but patients receiving opioids may develop somnolence, addiction, tolerance, and hyperalgesia [19].

Intravenous (IV) hemin is the standard of care for confirmed acute attacks [2, 20, 21]. Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [22–24]. Although hemin is not indicated for prophylaxis [22, 23], it is often used off-label for this purpose [11]. Some patients have reported recurrent attacks despite weekly prophylactic hemin administration [25]. Side effects and complications associated with hemin use include headache, infusion-site reactions, and phlebitis, and chronic complications, such as tachyphylaxis, coagulation abnormalities, venous damage, and secondary iron overload [25, 26]. Chronic hemin use is also associated with liver inflammation and fibrosis [25]. Patients may also have complications from the indwelling central venous catheter required to administer hemin on a regular basis, including catheter occlusion, bacteremia, and thrombembolism [25].
attacks requiring hospitalization, urgent health care, or IV administration of hemin at home in the previous 6 months [35]. Details regarding study subjects and methodology of the ENVISION study have been previously reported [35].

Thirty-six study sites in 18 countries participated in the study [35]. Patients were randomized to receive monthly subcutaneous givosiran 2.5 mg/kg or matching placebo for 6 months [35]. Randomization was stratified according to AHP subtype, previous use or nonuse of hemin prophylaxis, and a low or high AAR in the previous 12 months (< 7 attacks [low] vs. ≥ 7 attacks [high]) among patients who were receiving hemin prophylaxis at baseline and < 12 attacks [low] vs. ≥ 12 attacks [high] among those who were not receiving hemin prophylaxis) [35].

**Outcome measures**
The primary endpoint was AAR (requiring hospitalization, urgent health care, or IV administration of hemin at home) among patients with AIP [35]. Secondary endpoints included AAR among all patients with AHP; rate of administered hemin doses; daily worst scores for pain, fatigue, and nausea; and QOL assessments in patients with AIP. Exploratory endpoints included analgesic usage (opioid and non-opioid).

Daily worst pain and daily worst fatigue scores were measured using the Brief Pain Inventory-Short Form (BPI-SF) and Brief Fatigue Inventory-Short Form (BFI-SF) numerical rating scales (NRS), respectively. An NRS was also used for daily worst nausea score. All NRS ranged from 0 to 10, with higher scores indicating more severe symptoms; scores were captured using a daily eDiary from screening through Month 12.

QOL assessments included the 12-Item Short-Form Health Survey, version 2 (SF-12), and the EuroQol-5 Dimension-5 Level Questionnaire (EQ-5D-5L) and were collected throughout the study. The SF-12 generates 8 domains of functional health and well-being, including bodily pain, in addition to physical component summary (PCS) and mental component summary (MCS) scores. Low scores on the PCS indicate limitations in physical functioning, high bodily pain, and poor general health. The EQ-5D-5L assesses 5 dimensions, as well as patient’s global impression of their overall health on a visual analog scale (EQ VAS), which ranges from 0 (worst possible health) to 100 (best possible health).

**Post hoc analyses**
A review of ENVISION trial data was undertaken to fully examine the severity of AHP disease burden at baseline, including the prevalence of chronic symptoms, comorbidities, concomitant medications, prophylactic hemin use and associated complications, and patient QOL. Additional measurements included lost days of work due to AHP and hours of caregiver support required. The association between time since diagnosis and AAR was also examined. Furthermore, post hoc analyses were undertaken to examine the effects of givosiran treatment on the number and severity of attacks in patients with AHP according to prior hemin prophylaxis, and on daily worst pain scores and analgesic use during attack-free periods. These analyses were not protocol-defined, and therefore no formal statistical comparisons were undertaken.

**Results**
A total of 94 patients with AHP were enrolled in the ENVISION trial, of whom 46 were assigned to receive placebo and 48 to receive givosiran [35]. The median (range) age was 37.5 (19–65) years, and the mean (SD) years since diagnosis was 9.7 (10.0) [35]. The median (range) AAR in the 6 months prior to study randomization was 8.0 (0–46) [35].

At baseline, 52% of patients were experiencing chronic symptoms of porphyria, defined as symptoms between attacks daily or on most days [35]. Chronic symptoms included nausea, fatigue, and pain (Table 1). Opioid analgesics were used daily or on most days between attacks in 29% of patients [35]. Mean daily worst fatigue score was

| Characteristic                                      | Placebo (n = 46) | Givosiran (n = 48) | Total (N = 94) |
|-----------------------------------------------------|------------------|--------------------|----------------|
| Prior chronic symptoms, n (%)                       | 26 (57)          | 23 (48)            | 49 (52)        |
| Prior chronic opioid use, n (%)                     | 13 (28)          | 14 (29)            | 27 (29)        |
| Nausea symptoms (medical history), n (%)            | 10 (22)          | 7 (15)             | 17 (18)        |
| Fatigue (medical history), n (%)                    | 4 (9)            | 1 (2)              | 5 (5)          |
| Daily worst nausea score, weekly mean (SD)          | 1.9 (1.8)        | 1.6 (1.7)          | 1.7 (1.8)      |
| Daily worst fatigue score, weekly mean (SD)         | 4.7 (2.3)        | 4.1 (2.6)          | 4.4 (2.5)      |
| Daily worst pain score, weekly mean (SD)            | 3.7 (2.2)        | 3.0 (2.3)          | 3.3 (2.3)      |
| Bodily pain domain score (SF-12), mean (SD)         | 34.4 (9.0)       | 37.6 (9.9)         | 36.0 (9.6)     |
above 4, on a numerical rating scale of 0–10, in both treatment groups.

Patients had a poor QOL at baseline, as measured using the SF-12 PCS, SF-12 MCS, and EQ VAS (Table 2). While the study population was of working age (19–65 years), only 44% of patients were employed. Those who were employed missed a mean of 6 days and 3 days within the 4 weeks prior to their baseline visit in the placebo and givosiran group, respectively.

A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1). Sensory neuropathy was present in 19% of patients, motor neuropathy in 22% of patients, and autonomic neuropathy in 3% of patients. Overall rates of depression, anxiety, and insomnia were 27%, 23%, and 18%, respectively. A total of 29% of patients reporting being moderately, severely, or extremely anxious or depressed. Mean score for the SF-12 MCS was lower (40.9) than the population norm (50.0) \[37\], suggesting that AHP has a negative impact on mental health. Many patients were also taking concomitant medications that coincide with common comorbidities, including antidepressants, antihypertensives, antiemetics, and opioids (Table 3).

A high proportion of patients had received prior hemin prophylaxis (40%) \[11\], with many experiencing hemin-related complications, as well as ongoing damage caused by AHP (Fig. 2). Complications related to central venous access included thrombosis (8%), infection (18%), and catheter occlusion/malfunction (24%). Disease burden was also high in patients who had not received prior hemin prophylaxis (60%) (Table 4).

### Table 2: Quality of life in ENVISION trial participants at baseline

| Assessment                        | Placebo (n = 46)   | Givosiran (n = 48) |
|-----------------------------------|--------------------|--------------------|
| SF-12 PCS                         | 38.1 (9.8)         | 39.5 (9.8)         |
| SF-12 MCS                         | 41.8 (10.3)        | 39.9 (8.3)         |
| EQ VAS                            | 64.3 (19.6)        | 62.6 (22.6)        |
| Employed in past 4 weeks, n       | 21                 | 20                 |
| Days of work missed in past 4 weeks | 6.1 (6.5)       | 3.3 (3.5)          |
| Hours of caregiver support in past week | 11.3 (28.1)      | 12.5 (22.3)        |

EQ VAS EuroQol visual analog scale, MCS mental component summary, PCS physical component summary, SF-12 12-Item Short-Form Health Survey, version 2

**Fig. 1** Comorbidities in ENVISION trial participants at baseline
Table 3  Concomitant antidepressants, antihypertensives, antiemetics, and analgesics at baseline

|                                     | Placebo (n = 46) | Givosiran (n = 48) | Total (N = 94) |
|-------------------------------------|------------------|--------------------|----------------|
| **Antidepressants**                 |                  |                    |                |
| Benzodiazepine derivatives          | 10 (22)          | 10 (21)            | 20 (21)        |
| Benzodiazepine-related drugs        | 3 (7)            | 4 (8)              | 7 (7)          |
| Other anti-depressants              | 4 (9)            | 9 (19)             | 13 (14)        |
| SSRIs                               | 2 (4)            | 4 (8)              | 6 (6)          |
| **Antihypertensives**               |                  |                    |                |
| ACE inhibitors                      | 2 (4)            | 1 (2)              | 3 (3)          |
| Angiotensin II receptor antagonists | 3 (7)            | 2 (4)              | 5 (5)          |
| Beta blocking agents, non-selective| 1 (2)            | 3 (6)              | 4 (4)          |
| Beta blocking agents, selective     | 5 (11)           | 7 (15)             | 12 (13)        |
| **Antiemetics**                     |                  |                    |                |
| SHT3 antagonists                    | 12 (26)          | 12 (25)            | 24 (26)        |
| **Pain medications**                |                  |                    |                |
| Natural opium alkaloids             | 27 (59)          | 23 (48)            | 50 (53)        |
| Opioid anesthetics (fentanyl)       | 2 (4)            | 0                  | 2 (2)          |
| Opioid/non-opioid combinations      | 2 (4)            | 5 (10)             | 7 (7)          |
| Opium alkaloid derivatives          | 2 (4)            | 0                  | 2 (2)          |
| Other opioids                       | 8 (17)           | 6 (13)             | 14 (15)        |
| Other analgesics and antipyretics   | 10 (22)          | 13 (27)            | 23 (25)        |

SSRI selective serotonin reuptake inhibitor, ACE angiotensin-converting enzyme, SHT3 5-hydroxytryptamine

Fig. 2  Complications and comorbidities in ENVISION trial participants according to hemin prophylaxis at baseline
There was a linear relationship between longer time since diagnosis of AHP and higher AAR in the placebo group during the 6-month double-blind treatment period of the ENVISION trial (Fig. 3; $r = 0.403; P < 0.01$). This suggests that AHP disease worsening likely occurs over time.

The number of attacks, and attack severity, were both reduced in patients with AHP receiving givosiran compared with those receiving placebo, regardless of prior hemin use (Fig. 4). The total number of attacks among those with no prior hemin prophylaxis was 42 in the givosiran group versus 111 in the placebo group. Corresponding numbers among those who did have prior hemin prophylaxis were 48 and 186, respectively. The proportion of patients with $\geq 1$ attack, the proportion of attacks with a median pain score $\geq 7$, and the proportion of patients with $\geq 1$ attack with a median pain score $\geq 7$ were all lower in the givosiran group compared with the placebo group (Fig. 5).

AHP patients who received givosiran had reduced pain and analgesic use both during and between attacks compared with those who received placebo. Those in the givosiran group also had fewer days with daily worst pain scores above baseline (Fig. 6). Furthermore, they reported nearly 50% fewer days with severe pain during attack-free periods compared with placebo recipients (proportion of days with a pain score $\geq 7$; 7% vs. 12%). Opioid analgesics were used by 73% of patients in the givosiran group and 85% of patients in the placebo group during attacks [38]. Corresponding percentages during attack-free periods were 56% and 70%, respectively [38]. The proportion of days with opioid use was reduced in patients with AHP receiving givosiran compared with placebo, regardless of prior hemin use (Fig. 7). Givosiran treatment was also associated with improved QOL, measured by higher SF-12 PCS scores (Fig. 8).

### Table 4 Disease severity in ENVISION trial participants according to hemin prophylaxis at baseline

|                          | No prior hemin prophylaxis | Prior hemin prophylaxis |
|--------------------------|-----------------------------|-------------------------|
|                          | Placebo (n = 28)            | Givosiran (n = 28)      | Placebo (n = 18) | Givosiran (n = 20) |
| Historical AAR, median (range) | 6.0 (0–46)                 | 8.0 (4–34)               | 9.0 (4–38)       | 9.0 (4–32)       |
| Chronic symptoms, n (%)  | 17 (61)                     | 16 (57)                  | 9 (50)           | 7 (35)           |
| Chronic opioid use, n (%) | 7 (25)                      | 6 (21)                   | 6 (33)           | 8 (40)           |
| EQ VAS, mean (SD)        | 63.9 (20.7)                 | 58.4 (23.0)              | 64.8 (18.4)      | 68.4 (21.3)      |
| SF-12 PCS, mean (SD)     | 36.5 (10.5)<sup>a</sup>     | 39.3 (11.2)              | 40.5 (8.4)       | 39.7 (7.8)       |

AAR annualized attack rate, EQ VAS EuroQol visual analog scale, PCS physical component summary, SF-12 12-Item Short-Form Health Survey, version 2

<sup>a</sup> Data missing for 1 patient
Discussion

This study used data from the ENVISION trial to demonstrate the severe disease burden associated with recurrent AHP. At baseline, more than half of ENVISION trial patients were experiencing chronic symptoms between attacks, including nausea, fatigue, and pain, and more than one quarter had been using opioids daily or on most days [35]. We also found a positive correlation between
time since diagnosis and AHP disease severity, further highlighting the need to treat patients early with effective therapy. These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks.

Overall disease burden in the ENVISION trial population was similar to that observed in the recent EXPLORE study, a prospective, multinational, natural history study.
of patients with AHP experiencing recurrent attacks [11]. Eligibility criteria for EXPLORE were similar to the ENVISION trial, with EXPLORE patients needing to have experienced ≥ 3 attacks in the previous 12 months, including ≥ 1 attack requiring hemin or treatment at a hospital or healthcare setting, or be receiving prophylactic treatment to prevent attacks [11].
study entry in EXPLORE was 6 [11] compared with 8 in the ENVISION trial [35]. In EXPLORE, 46% of patients reported experiencing chronic porphyria symptoms daily [11] compared with 52% of patients in the ENVISION trial (symptoms daily or on most days) [35]. QOL at baseline, as assessed by EQ VAS, was diminished to a similar extent in EXPLORE (66) and ENVISION (about 63–64) [11]. Of note, rates of psychiatric disorders were higher in ENVISION than in EXPLORE (depression 27% vs. 18%, anxiety 23% vs. 8%, insomnia 18% vs. 12%, respectively) [11].

The proportions of patients with chronic symptoms in both ENVISION and EXPLORE (52–63%) were considerably higher than those reported in earlier US and Swedish observational studies (18–22%) [6, 11, 35, 39]. However, the rate of neuropathy in ENVISION (38%) was similar to that reported in the US observational study (43%) [6], and rates of kidney disease were also similar (25% and 29%) [6], suggesting that disease progression was comparable between studies.

The diagnosis of AHP is frequently delayed for years due to the non-specific nature of AHP symptoms [6]. In the US observational study of patients with symptomatic AHP, the mean time to disease diagnosis was 15 years [6]. Acute attacks in AHP can be difficult to distinguish from other common conditions [5, 40]. Delays in AHP diagnosis are often accompanied by inappropriate treatments for wrongly diagnosed conditions and unnecessary complications for the patient [41, 42]. Recurrent attacks of porphyria may lead to progressive or irreversible neuropathy and prolonged debilitation [2, 11].

Despite the high historical AAR, only about 50% of patients in ENVISION met the European Porphyria Network (EPNET) classification criteria for recurrent attacks, which are used as a marker for disease severity [43]. EPNET defines “recurrent” disease as ≥ 4 attacks in one or more years requiring hospitalization and hemin [43]. EPNET disease severity criteria do not include attacks requiring urgent care or hemin at home and do not include chronic symptoms of AHP. In comparison, the inclusion criteria for ENVISION required patients to have experienced ≥ 2 attacks requiring hospitalization, urgent care, or IV administration of hemin at home in the previous 6 months [35]. By using less-strict criteria for defining recurrent attacks, the ENVISION trial included patients across a range of disease severity in terms of the number of acute attacks and setting of acute attack treatment. This enabled an analysis of the long-term burden of AHP by accounting for multiple measures of disease severity, including chronic symptoms between attacks, pain severity and use of opioid analgesics, QOL and lost days of work, prevalence of comorbidities, prevalence of prophylactic hemin use, and complications associated with hemin prophylaxis [35]. Urgent healthcare visits and use of hemin at home for acute attacks accounted for 63% of historical AAR in the ENVISION trial.

Our study also examined disease burden at baseline according to prior hemin use in ENVISION trial patients and showed that disease burden remained high in patients who had not received hemin prophylaxis; approximately 60% experienced chronic symptoms between attacks, with a median historical AAR of 6 in the placebo group and 8 in the givosiran group.

In ENVISION, the number of porphyria attacks and attack severity were both reduced in patients receiving givosiran compared with those receiving placebo, regardless of prior hemin use. Givosiran recipients had fewer days with daily worst pain scores above baseline than placebo recipients, and nearly 50% fewer days with severe pain during attack-free periods. Pain is one of the key factors associated with diminished QOL among patients with AHP [11]. The SF-12 PCS scores increased by 10.0 and 8.9 points in the open-label extension in the placebo crossover and continuous givosiran groups, respectively. The proportion of patients who used opioid analgesics during attacks was 12% lower in the givosiran group compared with the placebo group during attacks, and 13% lower during attack-free periods. Given that long-term use of opioids is associated with tolerance, dependence, and addiction, a reduction in use of these medications is clinically relevant. Furthermore, evidence for the efficacy of opioids in the management of chronic non-cancer-related pain is limited. A 30-month open-label extension phase of ENVISION was completed in May 2021. Results to date support long-term maintenance of benefit with givosiran.

A strength of our study is that, unlike the observational EXPLORE study [11], all potential porphyria attacks occurring in the ENVISION trial were adjudicated by the investigator. A limitation of our study was the post hoc nature of our analyses and lack of prespecified formal statistical comparisons; therefore, the results should be interpreted carefully.

Conclusions
In conclusion, the current study highlights the severe disease burden associated with AHP, even in patients with a relatively low rate of attacks, and supports the effectiveness of givosiran for the management of certain acute and chronic porphyria symptoms.

Acknowledgements
Medical writing and editorial assistance were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alnylam Pharmaceuticals.
Author contributions
The authors interpreted the data, collaborated in manuscript preparation, and approved the submission of the article for publication. All authors read and approved the final manuscript.

Funding
Funding for this study was provided by the sponsor, Alnylam Pharmaceuticals. The protocol was developed by the sponsor, and data were collected by trial investigators and were analyzed by the sponsor.

Availability of data and materials
De-identified individual participant data that support these results will be made available in a secure-access environment 12 months after study completion. Access will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement.

Declarations
Ethics approval and consent to participate
The study was approved by central and local institutional review boards or ethics committees and was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
Bruce Wang reports being a scientific advisor to Alnylam Pharmaceuticals and Recordati Rare Diseases. Paolo Ventura reports receiving advisory board fees and lecture fees from Alnylam Pharmaceuticals and advisory board fees from Recordati Rare Diseases. Kei-ichiro Takase reports having nothing to disclose. Manish Thapar reports being a consultant and speaker for Alnylam. David Cassimian and the University of Leuven, University Hospital Leuven report receiving research grants, travel and conference bursaries, speaker fees, and advisory board compensation from a.o. Sanofi-Genzyme, Takeda-Shire, Alexion, Alnylam, BiolMarin, Actelion, Bayer, Roche, BMS, Schering-Plough, Synageva, and Chesi. Ilja Kubisch reports receiving fees from Alnylam. Simon A. Pumplius F, Querbes W, Wei A, Strutz S, Pienz C, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient. 2018;11(5):527–37.

Consent for publication
Not applicable.

Competing interests
Bruce Wang reports being a scientific advisor to Alnylam Pharmaceuticals and Recordati Rare Diseases. Paolo Ventura reports receiving advisory board fees and lecture fees from Alnylam Pharmaceuticals and advisory board fees from Recordati Rare Diseases. Kei-ichiro Takase reports having nothing to disclose. Manish Thapar reports being a consultant and speaker for Alnylam. David Cassimian and the University of Leuven, University Hospital Leuven report receiving research grants, travel and conference bursaries, speaker fees, and advisory board compensation from a.o. Sanofi-Genzyme, Takeda-Shire, Alexion, Alnylam, BiolMarin, Actelion, Bayer, Roche, BMS, Schering-Plough, Synageva, and Chesi. Ilja Kubisch reports receiving fees from Alnylam. Shang-bin Liu reports being an employee of and owning stock and stock options in Alnylam. Marianne T. Sweeeter reports being an employee of and owning stock and stock options in Alnylam. Manish Balwani reports receiving grant support, consulting fees, advisory board fees, and lecture fees from Alnylam Pharmaceuticals, advisory board fees from Recordati Rare Diseases, grant support and advisory board fees from Mitsubishi Tanabe, and advisory board fees from Alexion, Genzyme/Sanofi, and Takeda. In addition, Mount Sinai faculty are named co-investors with Alnylam on a patent related to the development of givosiran, the study drug. The Icahn School of Medicine at Mount Sinai receives payments related to this patent from Alnylam, and a portion of these payments are also distributed to faculty and other co-investors.

Author details
1. Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
2. University of Modena and Reggio Emilia, Modena, Italy.
3. Iizuka Hospital, Iizuka, Japan.
4. Thomas Jefferson University, Philadelphia, PA, USA.
5. University Hospital Leuven, Leuven, Belgium.
6. Klinikum Chemnitz, Chemnitz, Germany.
7. Alnylam Pharmaceuticals, Cambridge, MA, USA.
8. Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Received: 28 February 2022 Accepted: 24 July 2022
Published online: 26 August 2022

References
1. Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc: Hum Genet. 2015;86:17.20.1–17.20.6.
2. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–50.
3. Pea K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, et al. Hepato-cellular carcinoma in acute hepatic porphyrinas: a Damocles sword. Mol Genet Metab. 2019;128(3):236–41.
4. Pallet N, Karass A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J. 2018;11(2):191–7.
5. Bisell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3(1):17–26.
6. Bonkovsky HL, Maddukuri VC, Zayici C, Anderson KE, Bisell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233–41.
7. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849–57.
8. Silver S, Erwin AL, Meninger S, Ko JJ, Tkacz J, Nxon V, et al. Frequency of diagnosed acute intermittent porphyria in a national health care database [abstract 1025]. Am J Gastroenterol. 2019;114(supp):S587–8.
9. Schmitt C, Lengler H, Yu A, Delabuy C, Benecke A, Lefebvre T, et al. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Intern Med. 2018;284(1):78–91.
10. Simon A, Pumplius F, Querbes W, Wei A, Strutz S, Pienz C, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient. 2018;11(5):527–37.
11. Gouya L, Ventura P, Balwani M, Bisell DM, Rees DC, Stolzel U, et al. EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks. Hepatology (Baltimore, MD). 2020;71(5):1546–58.
12. Pallet N, Mami I, Schmitt C, Karim Z, Francois A, Rabant M, et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015;88(2):386–95.
13. Naik H, Stoeker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study. Mol Genet Metab. 2016;119(3):278–83.
14. Gill L, Burrell S, Chamberlayne J, Lombardelli S, Mora J, Mason N, et al., editors. Burden of illness in acute hepatic porphyria (AHP): insights from patient and caregiver representatives of the British Porphyria Association [poster]. International Congress on Porphyrias and Porphyrias; 2019 Sept 8–11, 2019 Milan, Italy.
15. Jeans JB, Savi K, Gross CR, Weimer MK, Bossenmaier IC, Piersch CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 1996;65(4):269–73.
16. Kothadia JP, LaFreniere K, Shah JM. Acute hepatic porphyria. Treasure Island: StatPearls Publishing; 2020.
17. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924–37.
18. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017;176(4):527–38.
19. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16.
20. Stolzel U, Doss MO, Schuppann D. Clinical guide and update on porphyrias. Gastroenterology. 2019;157(2):365–81.e4.
21. Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol. 2007;10(6):444–55.
22. Panhematin [package insert]. Lebanon: Recordati Rare Diseases Inc.; 2017 July.
23. Normosang [summary of product characteristics]. Bracknell: Recordati Rare Diseases UK Ltd; Dec 19, 2019.
24. Bonkovsky HL, Tschudy DP, Collins A, Doherty J, Bossenmaier I, Cardinal R, et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A. 1971;68(11):2725–9.
25. Downman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newcombe PN. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18(2):195–200.
26. Wang B, Rudnick S, Gengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019;3(2):193–206.
27. Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology (Baltimore, MD). 2014;60(3):1082–9.
28. Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, et al. Liver transplantation for acute intermittent porphyria. Liver Transpl. 2021;27(4):491–501.

29. Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maer M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4:e263.

30. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549–58.

31. Givlaari [package insert]. Cambridge: Alnylam Pharmaceuticals; Oct 2021.

32. Givlaari [summary of product characteristics] Amsterdam: Alnylam Netherlands; 2021 (Jan 1, 2021). https://www.ema.europa.eu/en/documents/product-information/givlaari-epar-product-information_en.pdf.

33. Givlaari Canada [product monograph]. Amsterdam: Alnylam Netherlands; 2020 Oct 2020.

34. Alnylam announces approval of GIVLAARI® (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults [press release]. Sao Paulo, Brazil: Alnylam Pharmaceuticals; 2020 (July 20, 2020). https://investors.alnylam.com/sites/default/files/GIVLAARI-Brazil-Approval-Press-Relea se.pdf.

35. Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–301.

36. Ventura P, Bonkovsky HL, Gouya L, Aguilera- Peiró P, Bissell DM, Stein PE, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2021;42(1):161–72.

37. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.

38. Kauppinen R, Kuo HC, Oh J, Hother-Nielson O, Petrides P, Kuter D, et al. Reduction in pain during and between attacks in patients with acute hepatic porphyria treated with givosiran: a posthoc analysis of the phase 3 ENVISION study [abstract O4015]. Eur J Neurol. 2020;27(suppl 1):96.

39. Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003;254(2):176–83.

40. Anderson KE. Acute hepatic porphyrias: current diagnosis & management. Mol Genet Metab. 2019;128(3):219–27.

41. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–14.

42. Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, et al. Acute intermittent porphyria: fatal complications of treatment. Clin Med (Lond). 2012;12(3):293–4.

43. Acute porphyria: European Porphyria Network; 2020 (updated Dec 7, 2020). https://porphyria.eu/en/content/acute-porphyria-0412.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.